Cited by 32Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Are Aβ and Its Derivatives Causative Agents or Innocent Bystanders in AD?

Open access
Robakis, Nikolaos K.·2010·Neurodegenerative Diseases

Abstract

Alzheimer’s disease (AD) is characterized by neurodegeneration in neocortical regions of the brain. Currently, Aβ-based theories, including amyloid depositions and soluble Aβ, form the basis of most therapeutic approaches to AD. It remains unclear, however, whether Aβ and its derivatives are the primary causative agents of neuronal loss in AD. Reported studies show no significant correlations between brain amyloid depositions and either degree of dementia or loss of neurons, and brain amyloid loads similar to AD are often found in normal individuals. Furthermore, behavioral abnormalities in animal models overexpressing amyloid precursor protein seem independent of amyloid depositions. Soluble Aβ theories propose toxic Aβ42 or its oligomers as the agents that promote cell death in AD. Aβ peptides, however, are normal components of human serum and CSF, and it is unclear under what conditions these peptides become toxic. Presently, there is little evidence of disease-associated abnormalities in soluble Aβ and no toxic oligomers specific to AD have been found. That familial AD mutations of amyloid precursor protein, PS1 and PS2 promote neurodegeneration suggests the biological functions of these proteins play critical roles in neuronal survival. Evidence shows that the PS/γ-secretase system promotes production of peptides involved in cell surface-to-nucleus signaling and gene expression, providing support for the hypothesis that familial AD mutations may contribute to neurodegeneration by inhibiting PS-dependent signaling pathways.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000266476

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Amyloid plaques are not innocent bystanders of the disease but induce a strong and coordinated response of all cell types in the amyloid plaque cellular niche.

    “The data demonstrate that amyloid plaques are not innocent bystanders of the disease as has been sometimes suggested (Robakis, 2010; Kametani and Hasegawa, 2018), but are in fact inducing a strong and coordinated response of all cell types in the amyloid plaque cellular niche (De Strooper and Karran, 2016).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 35 · Cited by 32

Research works printed but not linked: 5

  1. Glenner GG, Wong CW: Amyloidogenesis in Alzheimer's disease and Down's syndrome. Banbury Report 27: Mol Neuropath of Ag- ing. Cold Spring Harbor, Cold Spring Har- bor Press, 1987, pp 53-265.
  2. Bouras C, Kövari E, Herrmann FR, et al: Ste- reologic analysis of microvascular morphol- ogy in the elderly: Alzheimer disease pathol- ogy and cognitive status. J Neuropathol Exp Neurol 2006; 65: 235-244.
  3. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR: Alzheimer neuropatholog- ic alterations in aged cognitively normal sub- jects. J Neuropathol Exp Neurol 1999; 58: 376-388.
  4. Kumar-Singh S, Theuns J, Van Broeck B, et al: Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations cor- relates with both increased Abeta42 and de- creased Abeta40. Hum Mutat 2006; 27: 686- 695.
  5. Robakis NK: An Alzheimer's disease hy- pothesis based on transcriptional dysregula- tion. Amyloid 2003; 10: 80-85.

Authors
Robakis, N. K.
Affiliations
New York University (US)
Corresponding author
Robakis, Nikolaos K.
Venue
Neurodegenerative Diseases
Publisher
S. Karger AG
Published
2010
Volume
7
Issue
1-3
Pages
32-37
ISSN
  • 1660-2854 (ISSN-L)
  • 1660-2862
OpenAlex
W2039069687
Cited by
32
References
35
Citations by year
2026: 2 · 2023: 2 · 2020: 2 · 2018: 2 · 2016: 7 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
2.82
Type
journal article
Language
en
Open access
Locations
  • Neurodegenerative Diseases (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association (IIRG-06-26751)
  • National Institute on Aging (R37AG017926)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta, amyloid precursor protein, amyloid deposition, soluble amyloid-beta, amyloid-beta oligomers, amyloid-beta 42, neurodegeneration, neuronal loss, familial Alzheimer's disease mutations, presenilin, gamma-secretase, neurodegeneration mechanisms
MeSH terms
Alzheimer Disease, Animals, Humans, Models, Biological, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Presenilin-1, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review